Format

Send to

Choose Destination
Semin Fetal Neonatal Med. 2018 Aug;23(4):245-249. doi: 10.1016/j.siny.2018.03.008. Epub 2018 Mar 16.

Non-pharmacological management of a hemodynamically significant patent ductus arteriosus.

Author information

1
Department of Neonatology, The Rotunda Hospital, Dublin, Ireland.
2
Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada; Physiology and Experimental Medicine Program, Hospital for Sick Children Research Institute, Toronto, Ontario, Canada.
3
Department of Neonatology, The Rotunda Hospital, Dublin, Ireland; School of Medicine, Department of Paediatrics, Royal College of Surgeons in Ireland, Dublin, Ireland. Electronic address: afifelkhuffash@rcsi.com.

Abstract

The association between the patent ductus arteriosus (PDA) and neonatal morbidity, mortality and poor neurodevelopmental outcome in later childhood has been the focus of intense debate for decades. The lack of evidence supporting therapeutic strategies aimed at achieving PDA closure has led to the widespread adoption of conservative management aimed at mitigating the impact of shunt volume without achieving ductal closure. In this article, we review this management approach, describe the supportive evidence and potential complications associated with this strategy.

KEYWORDS:

Management; Patent ductus arteriosus

PMID:
29580939
DOI:
10.1016/j.siny.2018.03.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center